Chief investigator - Professor Richard Clark, University of Liverpool
DeEscalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia
Amount awarded: £160,530
Award start date: 01 Jun 2013
Recruitment start date: 01 Aug 2013
Award duration: 5 years

Almost all people with CML need to take drugs called tyrosine kinase inhibitors (TKIs), and a single daily pill can control their CML. But some people can’t tolerate the side effects of TKIs, or become resistant to the drugs over time. So researchers want to find ways to improve the quality of life of people with CML who are taking these drugs.

The DESTINY trial is investigating whether some people who are doing really well on their treatment for CML are being over-treated, and can remain well on either a lower dose of treatment or without treatment at all.

The dose of TKI drugs imatinib, nilotinib or dasatinib, is initially cut to half the standard dose for 12 months and then, in people who continue to do well, treatment is stopped completely for a further two years. This study will also help to develop a treatment decrease and stopping strategy for people who may develop CML in the future.

The aim of the study is to:

  • Determine the safety and efficacy of initially de-escalating and then stopping TKI treatment

This trial is closed for recruitment, and we reported promising year 1 results in December 2016.